Patients and their caregivers have enough to handle when dealing with cancer. At Aligned Therapeutics we align our success with patient outcomes by investing in therapeutic and diagnostic repurposement.

Most life sciences companies focus on developing proprietary therapeutics and diagnostics. Upon commercialization they keep exclusivity for years until competitors are allowed to produce cheaper alternatives. Little effort is dedicated to expanding use of old therapeutics as there is little money to be made from old treatments directly.  That’s where Aligned Therapeutics steps in. With our repurposement platform we pay for treatments and diagnostics ourselves. Instead of generating profits from selling treatments we work with insurance companies and providers directly to coordinate and provide care. We are then rewarded if patients achieve positive patient outcomes through our research tailoring unique treatment driven by each patient’s unique biology.

Our group is made up of representatives that have worked directly with the myriad of healthcare stakeholders: government affairs, market access, health economics, life sciences, and patient advocacy.

By bringing these generally isolated teams together with the sole focus of impacting patient outcomes the team at Aligned Therapeutics leverages three sets of tools to tailor coordinated personalized care.

01. Companion Diagnostics and Prognostics.

We repurpose available laboratory developed tests. With the specific focus predicting treatment response we leverage tumor mutational burden analysis linked to our research surfacing novel mechanisms of action.

02. Adjuvant Access and Treatments

We repurpose therapeutics, primarily small molecules. Many treatment options for patients are pre-determined by site of care and lags behind research innovation. With our knowledge of market access to personalized treatments linked to our ongoing repurposement research we can pave ways to access immunotherapies and even help patients get resensitized to treatments they have previously failed.

03. Real World Data and Partnerships.

We repurpose existing knowledge of patient outcomes. There is a wealth of data unavailable to most healthcare providers. We proactively partner with research groups, clinical networks, and foundations to produce real world evidence of comparative effectiveness research to begin the patient outcome driving efforts of repurposement research.

Each research line of Aligned Therapeutics consists of a laboratory developed diagnostic linked to an adjuvant treatment. For partnerships inquiries or potential collaborations reach out to our parent company at info@phageco.com for more information.

Our primary success has been in solid tumors. With a recent partnership with the Multiple Myeloma Foundation we have begun to look into developing research insights into blood cancers.

Our group is comprised of passionate patient advocates, industry leaders, and health economists pioneering novel routes to personalized patient outcomes.

Market access, value based care, therapeutic commercialization

KARLO MARTIN- CEO

Research, Information Management, Systems Modeling

SARA CITRENBAUM- COO

Finance, investor relations, corporate development

CHRISTIAN LIU- CFO

Government affairs, healthcare policy, product development

ASHTON RANDLE- CRO

Investor relations, contracting, corporate structuring

Jimmie Hicks- CLO

Thalia Sass- Process Engineer

We are always eager to hear from potential research collaborators or patients looking for personalized support with treatment options.